Hyloris Pharmaceuticals SA (EBR: HYL)
5.82
-0.08 (-1.36%)
Sep 4, 2024, 2:30 PM CET
Hyloris Pharmaceuticals Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
---|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
Cash & Equivalents | 29.77 | 29.77 | 41.76 | 89.44 | 6.38 | 15.13 | Upgrade
|
Short-Term Investments | - | - | 20 | - | - | - | Upgrade
|
Cash & Short-Term Investments | 29.77 | 29.77 | 61.76 | 89.44 | 6.38 | 15.13 | Upgrade
|
Cash Growth | -51.80% | -51.80% | -30.95% | 1301.49% | -57.82% | 74.60% | Upgrade
|
Other Receivables | 0.41 | 0.41 | 1.23 | 1.3 | 0.15 | 0.18 | Upgrade
|
Receivables | 0.41 | 0.41 | 1.23 | 1.3 | 0.15 | 0.18 | Upgrade
|
Restricted Cash | - | - | - | - | 0.02 | 0.01 | Upgrade
|
Other Current Assets | 1.24 | 1.24 | 1.19 | 1.64 | 0.42 | 0.17 | Upgrade
|
Total Current Assets | 31.42 | 31.42 | 64.18 | 92.39 | 6.97 | 15.49 | Upgrade
|
Property, Plant & Equipment | 2.09 | 2.09 | 2.1 | 2.38 | 0.4 | 0.47 | Upgrade
|
Goodwill | 1.85 | 1.85 | 1.9 | 1.7 | 1.61 | 1.73 | Upgrade
|
Other Intangible Assets | 7.96 | 7.96 | 8.26 | 8.33 | 5.22 | 5.65 | Upgrade
|
Long-Term Deferred Tax Assets | 0.31 | 0.31 | 0.16 | - | - | - | Upgrade
|
Total Assets | 43.63 | 43.63 | 76.59 | 104.8 | 14.19 | 23.35 | Upgrade
|
Accounts Payable | 1.37 | 1.37 | 1.91 | 0.95 | 0.91 | 1.31 | Upgrade
|
Accrued Expenses | 1.73 | 1.73 | 2.32 | 1.9 | 1.21 | 0.68 | Upgrade
|
Current Portion of Leases | 0.57 | 0.57 | 0.43 | 0.47 | 0.14 | 0.13 | Upgrade
|
Current Income Taxes Payable | 0.22 | 0.22 | 0.22 | 0.08 | 0.03 | 0.04 | Upgrade
|
Current Unearned Revenue | 1.83 | 1.83 | 1.33 | - | 0.1 | 0.22 | Upgrade
|
Other Current Liabilities | 0.96 | 0.96 | 2.02 | 2.14 | 0.28 | 0.34 | Upgrade
|
Total Current Liabilities | 6.68 | 6.68 | 8.22 | 5.54 | 2.67 | 2.71 | Upgrade
|
Long-Term Debt | 15.26 | 15.26 | 12.66 | 11.45 | 41.82 | 33.48 | Upgrade
|
Long-Term Leases | 1.05 | 1.05 | 1.29 | 1.74 | 0.06 | 0.2 | Upgrade
|
Long-Term Deferred Tax Liabilities | 0.63 | 0.63 | 0.67 | 1.99 | 1.34 | 1.45 | Upgrade
|
Total Liabilities | 25.7 | 25.7 | 23.96 | 22.11 | 46.29 | 38.27 | Upgrade
|
Common Stock | 3.62 | 3.62 | 3.62 | 3.62 | - | - | Upgrade
|
Additional Paid-In Capital | 155.25 | 155.25 | 155.25 | 155.25 | 3.08 | 3.08 | Upgrade
|
Retained Earnings | -145.43 | -145.43 | -108.32 | -75.97 | -53.11 | -32.92 | Upgrade
|
Comprensive Income & Other | 4.49 | 4.49 | 2.08 | -0.21 | 3.14 | 0.67 | Upgrade
|
Total Common Equity | 17.93 | 17.93 | 52.63 | 82.68 | -46.89 | -29.17 | Upgrade
|
Shareholders' Equity | 17.93 | 17.93 | 52.63 | 82.68 | -32.1 | -14.92 | Upgrade
|
Total Liabilities & Equity | 43.63 | 43.63 | 76.59 | 104.8 | 14.19 | 23.35 | Upgrade
|
Total Debt | 16.87 | 16.87 | 14.38 | 13.67 | 42.02 | 33.8 | Upgrade
|
Net Cash (Debt) | 12.89 | 12.89 | 47.38 | 75.78 | -35.63 | -18.67 | Upgrade
|
Net Cash Growth | -72.79% | -72.79% | -37.47% | - | - | - | Upgrade
|
Net Cash Per Share | 0.43 | 0.43 | 1.57 | 7.99 | -9.90 | -6.19 | Upgrade
|
Filing Date Shares Outstanding | 30.18 | 30.18 | 30.18 | 30.18 | 9.58 | 3.02 | Upgrade
|
Total Common Shares Outstanding | 30.18 | 30.18 | 30.18 | 30.18 | 9.58 | 3.02 | Upgrade
|
Working Capital | 24.74 | 24.74 | 55.96 | 86.85 | 4.3 | 12.78 | Upgrade
|
Book Value Per Share | 0.59 | 0.59 | 1.74 | 2.74 | -4.89 | -9.67 | Upgrade
|
Tangible Book Value | 8.13 | 8.13 | 42.47 | 72.65 | -53.71 | -36.55 | Upgrade
|
Tangible Book Value Per Share | 0.27 | 0.27 | 1.41 | 2.41 | -5.61 | -12.11 | Upgrade
|
Machinery | 1.28 | 1.28 | 0.92 | 0.8 | 0.71 | 0.54 | Upgrade
|
Leasehold Improvements | 0.34 | 0.34 | 0.27 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.